Dermatologie (Heidelberg, Germany) · 2026
[Chronic prurigo: overview of pathophysiology, diagnosis, and treatment].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Witte Felix, Zeidler Claudia, Ständer Sonja
Аннотация
BACKGROUND: Chronic prurigo (CPG) remains a challenging disease. Besides diagnosis, which mostly relies on the S2k-guideline diagnosis and treatment of chronic pruritus, two systemic agents have been approved for the treatment of CPG in recent years.
OBJECTIVES: This review aims to provide an overview of the pathophysiology and current diagnostic and therapeutic recommendations for CPG.
MATERIALS AND METHODS: For this review, a literature and clinical trial search was conducted via PubMed and Clinical Trials using the terms 'chronic prurigo', 'prurigo nodularis', 'pathophysiology', 'diagnosis', 'treatment' and 'therapy'.
RESULTS AND CONCLUSION: The pathophysiology of CPG is becoming increasingly well understood. Building on this, a second targeted therapy for patients with moderate to severe CPG has recently been approved. Numerous other substances are currently undergoing clinical trials, offering the prospect of further improvements in the care of patients affected by CPG.
OBJECTIVES: This review aims to provide an overview of the pathophysiology and current diagnostic and therapeutic recommendations for CPG.
MATERIALS AND METHODS: For this review, a literature and clinical trial search was conducted via PubMed and Clinical Trials using the terms 'chronic prurigo', 'prurigo nodularis', 'pathophysiology', 'diagnosis', 'treatment' and 'therapy'.
RESULTS AND CONCLUSION: The pathophysiology of CPG is becoming increasingly well understood. Building on this, a second targeted therapy for patients with moderate to severe CPG has recently been approved. Numerous other substances are currently undergoing clinical trials, offering the prospect of further improvements in the care of patients affected by CPG.